ArticlebioRxiv : the preprint server for biology2025
NKX2-5 congenital heart disease mutations show diverse loss and gain of epigenomic, biochemical and chromatin search functions underpinning pathogenicity.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Congenital heart defects (CHD) occur in ~1% of live births, with both inherited and acquired mutations and environmental factors known to contribute to causation. However, network perturbations and epigenetic changes in CHD remain poorly characterised. We report an integrated functional-epigenomics approach to understanding CHD, focusing on the cardiac homeodomain (HD) family transcription factor NKX2-5, mutations in which cause diverse congenital heart structural and conduction defects. We selected twelve NKX2-5 CHD-associated variants affecting different residue classes - DNA base-contacting, backbone-contacting, helix-stabilizing residues of the homeodomain, and those affecting other conserved protein:protein interaction (PPI) domains. In HL-1 cardiomyocytes, we profiled DNA targets of NKX2-5 wild type (WT) and variant proteins genome-wide using DamID, their DNA binding affinity and specificity using comprehensive protein binding microarrays, and PPI with known NKX2-5 cofactors using yeast 2-hybrid assay. We also undertook deep profiling of chromatin search and binding dynamics using single molecule tracking. Variants showed highly diverse but also class-specific behaviours with a range of severities. All variants failed to bind many WT targets but retained binding to a subset of core cardiomyocyte-related WT NKX2-5 targets, as well as hundreds of unique "off-targets", in part via a regulatory logic that included changes to DNA binding site specificity, homodimerization and lost or enhanced cofactor interactions. All variants tested showed altered chromatin search functions. Our data suggest that complex residue-by-residue scale epigenomic, biochemical and chromatin search perturbations, involving both loss- and gain-of-function, contribute to CHD phenotypes. These findings may inform precision molecular therapeutic approaches in patients with CHD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.